Reprogramming the tumor microenvironment by rational immune gene therapy: From in vivo CRISPRa screening to combination design

The past decade of cancer immunotherapy has revealed a paradox: while the immune system possesses extraordinary anti-tumor potential, most solid tumors remain refractory to treatment due to a profoundly suppressive tumor microenvironment (TME). Efforts to overcome this barrier have largely relied on single-axis interventions, such as checkpoint blockade or isolated cytokine therapies, yet durable responses remain limited. In this context, the recent study by Zhang et al. in Cancer Discovery introduces a conceptually important advance: rather than beginning with a preselected cytokine or checkpoint target, they built an in vivo CRISPR activation (CRISPRa) platform to interrogate immune-regulatory nodes directly within the TME, leveraging the resulting signal map to rationally assemble combination gene therapies.

The broader importance of this study is not simply that it identifies a potent gene combination but that it reframes the TME as a tractable design space for therapeutic bioengineering. Rather than pursuing another isolated immune target, Zhang et al. adopt a combinatorial logic that reflects the biological realities of solid tumors, where immune exclusion, stromal confinement, and metabolic suppression often coexist. The authors organized their screening library around antigen presentation, proliferation, costimulatory molecules, and migration—an APCM framework that mirrors the fundamental requirements for productive anti-tumor immunity. Through iterative in vivo screening and subtractive validation, the study converged on a minimal yet highly effective combination consisting of TNFSF9 (4-1BBL), IFNG, and IL12B, collectively termed 4II.

Importantly, this APCM-guided strategy represents a distinct approach when viewed alongside other emerging TME reprogramming modalities. For example, TGF-β blockade primarily seeks to overcome stromal exclusion and improve immune infiltration, whereas metabolic reprogramming strategies attempt to restore T cell function by reversing hypoxia, lactate accumulation, and nutrient deprivation within tumors. In contrast, the 4II combination functions as an active and multi-pronged immune-conditioning platform that simultaneously enhances antigen presentation, inflammatory signaling, and T cell costimulation. Thus, rather than competing with current immunotherapies, the APCM strategy may serve as a biologically complementary platform capable of sensitizing tumors to immune checkpoint inhibitors or adoptive cell therapies.

Biologically, the final combination is compelling because it addresses three distinct barriers at once. IFNG can promote antigen presentation and inflammatory activation; TNFSF9/4-1BBL provides a potent costimulatory cue that supports T cell expansion and persistence; and IL12B, by supporting IL-12/IL-23 family signaling, reinforces inflammatory polarization and cytotoxicity. The authors’ data show that adeno-associated virus (AAV)-mediated expression of these factors increases total CD45+ immune infiltration, CD8+ T cell abundance, IFN-γ-producing CD8+ cells, and tissue-resident memory CD8+ T cells, significantly outperforming single-gene delivery. This is a meaningful design principle: in solid tumors, durable immune control usually requires simultaneous enhancement of trafficking, activation, and persistence, not isolated stimulation of one axis.